| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0960-0760(95)00134-L |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:096007609500134L?httpAccept=text/xml |
| https://api.elsevier.com/content/article/PII:096007609500134L?httpAccept=text/plain | ||
| P698 | PubMed publication ID | 7577710 |
| P50 | author | Rothwelle J Tate | Q63874643 |
| P2093 | author name string | J. P. Raynaud | |
| P. M. Martin | |||
| C. Iehlé | |||
| S. Délos | |||
| O. Guirou | |||
| P2860 | cites work | Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue | Q24297868 |
| Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism | Q24311401 | ||
| Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression | Q24596101 | ||
| Molecular genetics of steroid 5 alpha-reductase 2 deficiency | Q24619385 | ||
| Structure of human type II 5 alpha-reductase gene | Q29038931 | ||
| Inhibition of steroid 5α-reductase by specific aliphatic unsaturated fatty acids | Q33992498 | ||
| Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073). | Q34338255 | ||
| Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. | Q34344637 | ||
| Uses and limitations of hormone, receptor and enzyme assays in prostate cancer | Q39671234 | ||
| Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells | Q41482572 | ||
| Baculovirus-directed expression of human prostatic steroid 5 alpha-reductase 1 in an active form | Q41534676 | ||
| Partial purification of human prostatic 5 alpha-reductase (3-oxo-5 alpha-steroid:NADP+ 4-ene-oxido-reductase; EC 1.3.1.22) in a stable and active form | Q48822830 | ||
| Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. | Q53846421 | ||
| Specific stimulation of steroid 5 alpha-reductase solubilized from rat liver microsomes by endogenous phosphatidylserine | Q68531222 | ||
| Solubilization of human prostatic 5 alpha-reductase | Q70116150 | ||
| Response of Rat Ventral Prostate to a New and Novel 5αa-Reductase Inhibitor | Q70870392 | ||
| Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts | Q71305133 | ||
| Species differences in prostatic steroid 5 alpha-reductases of rat, dog, and human | Q93596529 | ||
| P433 | issue | 5-6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 273-279 | |
| P577 | publication date | 1995-09-01 | |
| P1433 | published in | The Journal of Steroid Biochemistry and Molecular Biology | Q15708871 |
| P1476 | title | Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors | |
| Human prostatic steroid 5α-reductase isoforms—A comparative study of selective inhibitors | |||
| P478 | volume | 54 |
| Q28266588 | A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro |
| Q53243983 | A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. |
| Q79218992 | American Association of Clinical Endocrinologists Medical Guidelines for the Clinical Use of Dietary Supplements and Nutraceuticals |
| Q51577802 | Aqueous leaf extracts display endocrine activities in vitro and disrupt sexual differentiation of male Xenopus laevis tadpoles in vivo. |
| Q35407450 | Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results |
| Q91800302 | Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis |
| Q44035128 | Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study |
| Q91991219 | Complementary and Alternative Treatments for Alopecia: A Comprehensive Review |
| Q34348296 | Complementary and alternative therapies for advanced prostate cancer |
| Q33602452 | Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. |
| Q73064908 | Determination of turosteride, a new inhibitor of 5 alpha-reductase, in human plasma by high-performance liquid chromatography with ultraviolet detection |
| Q78030401 | Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue |
| Q34470170 | Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats |
| Q73911110 | Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils |
| Q34313221 | Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation |
| Q37672774 | Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study |
| Q40215681 | Effects of Saw Palmetto Extract on Urodynamic Parameters, Bladder Muscarinic and Purinergic Receptors and Urinary Cytokines in Rats with Cyclophosphamide-Induced Cystitis |
| Q55068039 | Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. |
| Q37828063 | Estrogen and androgen signaling in the pathogenesis of BPH. |
| Q33187577 | Extracts of various species of Epilobium inhibit proliferation of human prostate cells. |
| Q37235402 | Fatty acid and phytosterol content of commercial saw palmetto supplements. |
| Q37663475 | In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity |
| Q34164024 | Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon |
| Q77499019 | Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5alpha-reductase activity |
| Q35869909 | Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride. |
| Q34469844 | PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor |
| Q37406930 | Pharmacological effects of saw palmetto extract in the lower urinary tract |
| Q28204203 | Phytomedicines for the prostate |
| Q34526601 | Phytotherapy for Benign Prostatic Hyperplasia |
| Q34707794 | Phytotherapy for chronic prostatitis |
| Q58147794 | Phytotherapy for prostatism |
| Q33591029 | Phytotherapy in the treatment of benign prostatic hyperplasia: an update |
| Q36021075 | Preventing diseases of the prostate in the elderly using hormones and nutriceuticals |
| Q36598330 | Preventing progression in men with mild symptoms of benign prostatic hyperplasia: a potential role for phytotherapy. |
| Q80296383 | Saw Palmetto Berry as a Treatment for BPH |
| Q36174671 | Saw palmetto and finasteride in the treatment of category-III prostatitis/chronic pelvic pain syndrome |
| Q42828508 | Saw palmetto ethanol extract inhibits adipocyte differentiation |
| Q31156179 | Semiquantitative RT-PCR method coupled to capillary electrophoresis to study 5alpha-reductase mRNA isozymes in rat ventral prostate in different androgen status |
| Q41217704 | Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia |
| Q40787267 | Stable expression of the human 5alpha-reductase isoenzymes type I and type II in HEK293 cells to identify dual and selective inhibitors |
| Q51792401 | Subcellular localization of the five members of the human steroid 5α-reductase family. |
| Q34239009 | The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride |
| Q50195959 | The influence of benign prostatic hyperplasia on sperm morphological features and sperm DNA integrity in dogs |
| Q48183066 | Treatment of male androgenetic alopecia with topical products containing Serenoa repens extract. |
| Q40801899 | Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease |
| Q91740309 | Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia |
| Q24794475 | Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer c |
Search more.